Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Long

Showing results (231-240 of 703) with videos related to

Pageof 71
Sort By:
The Journal of Clinical Endocrinology and Metabolism|February 1, 2022
Association of Antithyroid Antibodies in Checkpoint Inhibitor-Associated Thyroid Immune-Related Adverse EventsChristopher A Muir, Cameron C G Wood, Roderick J Clifton-Bligh, et al.
Journal for Immunotherapy of Cancer|June 8, 2025
Hyperglycemia in patients treated with immune checkpoint inhibitors: key clinical challenges and multidisciplinary consensus recommendationsLinda Wu, Venessa Tsang, Roderick Clifton-Bligh, et al.
The Lancet. Oncology|November 20, 2016
Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trialsGeorgina V Long, Jean-Jacques Grob, Paul Nathan, et al.
Molecular Oncology|January 31, 2014
Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanomaMatteo S Carlino, Jason R Todd, Kavitha Gowrishankar, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 15, 2018
Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancerG V Long, S S Tykodi, J G Schneider, et al.
Pigment Cell & Melanoma Research|April 5, 2013
Meeting report from the Society for Melanoma Research 2012 Congress, Hollywood, CaliforniaR S Lo, A Ribas, G V Long, et al.
Critical Reviews in Oncology/Hematology|June 22, 2025
Predictive performance of the clinicopathologic gene expression profile (CP-GEP) in identifying cutaneous melanoma patients for whom sentinel lymph node biopsy is unnecessary: A systematic review and meta-analysisTerence Wong, Sydney Ch'ng, Peter Ferguson, et al.
Molecular Cancer Therapeutics|September 11, 2012
Intratumoral molecular heterogeneity in a BRAF-mutant, BRAF inhibitor-resistant melanoma: a case illustrating the challenges for personalized medicineJames S Wilmott, Varsha Tembe, Julie R Howle, et al.
European Journal of Cancer (Oxford, England : 1990)|November 18, 2020
Management of melanoma brain metastases: Evidence-based clinical practice guidelines by Cancer Council AustraliaAngela M Hong, Cora Waldstein, Brindha Shivalingam, et al.
JAMA Oncology|February 10, 2018
Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti-Programmed Cell Death 1 AntibodiesJenny H Lee, Georgina V Long, Alexander M Menzies, et al.
Pageof 71

Showing results (231-240 of 703) with videos related to

Sort By:
Pageof 71
The Journal of Clinical Endocrinology and Metabolism|February 1, 2022
Association of Antithyroid Antibodies in Checkpoint Inhibitor-Associated Thyroid Immune-Related Adverse EventsChristopher A Muir, Cameron C G Wood, Roderick J Clifton-Bligh, et al.
Journal for Immunotherapy of Cancer|June 8, 2025
Hyperglycemia in patients treated with immune checkpoint inhibitors: key clinical challenges and multidisciplinary consensus recommendationsLinda Wu, Venessa Tsang, Roderick Clifton-Bligh, et al.
The Lancet. Oncology|November 20, 2016
Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trialsGeorgina V Long, Jean-Jacques Grob, Paul Nathan, et al.
Molecular Oncology|January 31, 2014
Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanomaMatteo S Carlino, Jason R Todd, Kavitha Gowrishankar, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 15, 2018
Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancerG V Long, S S Tykodi, J G Schneider, et al.
Pigment Cell & Melanoma Research|April 5, 2013
Meeting report from the Society for Melanoma Research 2012 Congress, Hollywood, CaliforniaR S Lo, A Ribas, G V Long, et al.
Critical Reviews in Oncology/Hematology|June 22, 2025
Predictive performance of the clinicopathologic gene expression profile (CP-GEP) in identifying cutaneous melanoma patients for whom sentinel lymph node biopsy is unnecessary: A systematic review and meta-analysisTerence Wong, Sydney Ch'ng, Peter Ferguson, et al.
Molecular Cancer Therapeutics|September 11, 2012
Intratumoral molecular heterogeneity in a BRAF-mutant, BRAF inhibitor-resistant melanoma: a case illustrating the challenges for personalized medicineJames S Wilmott, Varsha Tembe, Julie R Howle, et al.
European Journal of Cancer (Oxford, England : 1990)|November 18, 2020
Management of melanoma brain metastases: Evidence-based clinical practice guidelines by Cancer Council AustraliaAngela M Hong, Cora Waldstein, Brindha Shivalingam, et al.
JAMA Oncology|February 10, 2018
Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti-Programmed Cell Death 1 AntibodiesJenny H Lee, Georgina V Long, Alexander M Menzies, et al.
Pageof 71